Table 2.

Second RA cohort disease distribution.

	RA subjects (n = 52)
Age at draw (mean ± SD years)	57.3 ± 14.3
Male/Female	14/38
Race	92.3% Caucasian,7.7% other
Disease duration (mean ± SD years)	13.5 ± 10.8
RAPID3 score	2.6 ± 1.7
CCP+	86.5%
RF+	61.5%
Therapy	30% Steroid 75% DMARD 36.5% NSAID 55.8% Biologic

RAPID3, the routine assessment of patient index data with 3 measures (0–9); CCP, cyclic citrullinated peptide; RF, rheumatoid factor. Steroid therapy includes: prednisone (5–20 mg/day); DMARD includes: methotrexate (10–25 mg/week or 10 mg/2X weekly), sulfasalazine, hydroxychloroquine (200 mg/2X or 1X daily), NSAID includes: ibuprofen, naproxen, aspirin, meloxicam, and celecoxib; and biologics includes: golimumab, etanercept, abatacept, infliximab, tofacitinib, and adalimumab.